This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Rejuvenation: Difference between revisions
>Josikins proofreading effect categories |
>Josikins grammatical overhaul |
||
| Line 6: | Line 6: | ||
There are a number of legitimate scientific studies which have concluded that long lasting mental benefits can occur after a drug has been taken. For example, it has been demonstrated that ketamine, even if taken in small doses, is effective for patients suffering from chronic depression and bipolar disorder. Studies have shown<ref>Ketamine Improves Bipolar Depression Within Minutes - http://www.medicaldaily.com/articles/10085/20120530/ketamin-bipolar-disorder-depression.htm</ref><ref>Could A Club Drug Offer 'Almost Immediate' Relief From Depression? - http://www.npr.org/blogs/health/2012/01/30/145992588/could-a-club-drug-offer-almost-immediate-relief-from-depression</ref> that the effect of the drug is immediate or within 2 hours and consistent in relieving a patient’s depressive and/or suicidal symptoms, lasting up to 3 days after a single dose. | There are a number of legitimate scientific studies which have concluded that long lasting mental benefits can occur after a drug has been taken. For example, it has been demonstrated that ketamine, even if taken in small doses, is effective for patients suffering from chronic depression and bipolar disorder. Studies have shown<ref>Ketamine Improves Bipolar Depression Within Minutes - http://www.medicaldaily.com/articles/10085/20120530/ketamin-bipolar-disorder-depression.htm</ref><ref>Could A Club Drug Offer 'Almost Immediate' Relief From Depression? - http://www.npr.org/blogs/health/2012/01/30/145992588/could-a-club-drug-offer-almost-immediate-relief-from-depression</ref> that the effect of the drug is immediate or within 2 hours and consistent in relieving a patient’s depressive and/or suicidal symptoms, lasting up to 3 days after a single dose. | ||
A similar example includes a study which observed significantly decreased depression scores in terminal cancer patients six months after treatment with psilocybin.<ref>Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. ''Archives of General Psychiatry'', 68(1), 71-78. https://doi.org/10.1001/archgenpsychiatry.2010.116</ref> An open-label study was carried out in 2016 in the UK to investigate the feasibility, safety and efficacy of psilocybin in treating patients with unipolar treatment-resistant depression with promising results; although the study was small and involved only twelve patients, seven of those patients met formal criteria for remission one week following psilocybin treatment and five of those were still in remission from their depression at three months.<ref>Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., ... & Taylor, D. (2016). [http://www.thelancet.com/pdfs/journals/lanpsy/PIIS2215-0366(16)30065-7.pdf Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study]. ''The Lancet Psychiatry'', 3(7), 619-627. https://doi.org/10.1016/S2215-0366(16)30065</ref> | A similar example includes a study which observed significantly decreased depression scores in terminal cancer patients six months after treatment with psilocybin.<ref>Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. ''Archives of General Psychiatry'', 68(1), 71-78. https://doi.org/10.1001/archgenpsychiatry.2010.116</ref> An open-label study was carried out in 2016 in the UK to investigate the feasibility, safety, and efficacy of psilocybin in treating patients with unipolar treatment-resistant depression with promising results; although the study was small and involved only twelve patients, seven of those patients met formal criteria for remission one week following psilocybin treatment and five of those were still in remission from their depression at three months.<ref>Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., ... & Taylor, D. (2016). [http://www.thelancet.com/pdfs/journals/lanpsy/PIIS2215-0366(16)30065-7.pdf Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study]. ''The Lancet Psychiatry'', 3(7), 619-627. https://doi.org/10.1016/S2215-0366(16)30065</ref> | ||
===Psychoactive substances=== | ===Psychoactive substances=== | ||
Compounds within our [[psychoactive substance index]] which may cause this effect include: | Compounds within our [[psychoactive substance index]] which may cause this effect include: | ||